{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:58:51Z","timestamp":1790758731381,"version":"4.1.0"},"reference-count":65,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>RET rearrangements are observed in 1\u20132% of non-small-cell lung cancer (NSCLC) patients and result in the constitutive activation of downstream pathways normally implied in cell proliferation, growth, differentiation and survival. In NSCLC patients, RET rearrangements have been associated with a history of non-smoking, a higher rate of brain metastasis at initial diagnosis and a low immune infiltrate. Traditionally, RET fusions are considered mutually exclusive with other oncogenic drivers, even though a co-occurrence with EGFR mutations and MET amplifications has been observed. Cabozantinib, vandetanib and lenvatinib are the first multi-kinase inhibitors tested in RET-rearranged NSCLC patients with contrasting results. More recently, two selective RET inhibitors, selpercatinib and pralsetinib, demonstrated higher efficacy rates and good tolerability and they were approved for the treatment of patients with metastatic RET fusion-positive NSCLC on the bases of the results of phase II studies. Two ongoing phase III clinical trials are currently comparing selpercatinib or pralsetinib to standard first line treatments and will definitively establish their efficacy in RET-positive NSCLC patients.<\/jats:p>","DOI":"10.3390\/cancers13174415","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:39:03Z","timestamp":1630496343000},"page":"4415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["RET Inhibitors in Non-Small-Cell Lung Cancer"],"prefix":"10.3390","volume":"13","author":[{"given":"Priscilla","family":"Cascetta","sequence":"first","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-3854","authenticated-orcid":false,"given":"Vincenzo","family":"Sforza","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Manzo","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-9432","authenticated-orcid":false,"given":"Guido","family":"Carillio","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Azienda Ospedaliera Pugliese-Ciaccio, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Montanino","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sandomenico","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"De Cecio","sequence":"additional","affiliation":[{"name":"Department of Pathology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Piccirillo","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"La Manna","sequence":"additional","affiliation":[{"name":"Thoracic Surgery, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Totaro","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Picone","sequence":"additional","affiliation":[{"name":"Department of Radiology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7158-2605","authenticated-orcid":false,"given":"Nicola","family":"Normanno","sequence":"additional","affiliation":[{"name":"Cellular Biology and Biotherapy and Scientific Directorate, Istituto Nazionale Tumori, \u201cFondazione G.Pascale\u201d IRCCS, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-9608","authenticated-orcid":false,"given":"Alessandro","family":"Morabito","sequence":"additional","affiliation":[{"name":"Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS \u201cFondazione G. Pascale\u201d, 80131 Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.cellsig.2004.10.012","article-title":"Direct Interactions among Ret, GDNF and GFR\u03b11 Molecules Reveal New Insights into the Assembly of a Functional Three-Protein Complex","volume":"17","author":"Amoresano","year":"2005","journal-title":"Cell Signal"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Li, A.Y., McCusker, M.G., Russo, A., Scilla, K.A., Gittens, A., Arensmeyer, K., Mehra, R., Adamo, V., and Rolfo, C. (2019). RET Fusions in Solid Tumors. Cancer Treat. Rev., 81.","DOI":"10.1016\/j.ctrv.2019.101911"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1158\/1078-0432.CCR-20-1587","article-title":"Progresses Toward Precision Medicine in RET-Altered Solid Tumors","volume":"26","author":"Belli","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.lungcan.2016.09.002","article-title":"Clinicopathologic Characteristics, Genetic Variability and Therapeutic Options of RET Rearrangements Patients in Lung Adenocarcinoma","volume":"101","author":"Song","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jtho.2015.09.016","article-title":"Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients","volume":"11","author":"Michels","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2015.06.021","article-title":"Emergence of RET Rearrangement Co-Existing with Activated EGFR Mutation in EGFR-Mutated NSCLC Patients Who Had Progressed on First- or Second-Generation EGFR TKI","volume":"89","author":"Klempner","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and Translational Implications of RET Rearrangements in Non\u2013Small Cell Lung Cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00432-020-03267-x","article-title":"Comparison of Liquid-Based to Tissue-Based Biopsy Analysis by Targeted next Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review","volume":"146","author":"Esagian","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2013.07.009","article-title":"Diagnostic Method for the Detection of KIF5B-RET Transformation in Lung Adenocarcinoma","volume":"82","author":"Go","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53336","DOI":"10.18632\/oncotarget.18408","article-title":"Clinicopathological Characteristics of ROS1 - and RET -Rearranged NSCLC in Caucasian Patients: Data from a Cohort of 713 Non-Squamous NSCLC Lacking KRAS\/EGFR\/HER2\/BRAF\/PIK3CA\/ALK Alterations","volume":"8","author":"Dugay","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hess, L.M., Han, Y., Zhu, Y.E., Bhandari, N.R., and Sireci, A. (2021). Characteristics and Outcomes of Patients with RET-Fusion Positive Non-Small Lung Cancer in Real-World Practice in the United States. BMC Cancer, 21.","DOI":"10.1186\/s12885-020-07714-3"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/JTO.0000000000000015","article-title":"RET Rearrangements in Lung Adenocarcinoma and Radiation","volume":"9","author":"Dacic","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2014.36","article-title":"RET-Rearranged Non-Small-Cell Lung Carcinoma: A Clinicopathological and Molecular Analysis","volume":"110","author":"Tsuta","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/JTO.0000000000000323","article-title":"RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib","volume":"9","author":"Mukhopadhyay","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Digumarthy, S.R., Mendoza, D.P., Lin, J.J., Rooney, M., Do, A., Chin, E., Yeap, B.Y., Shaw, A.T., and Gainor, J.F. (2020). Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements. Cancers, 12.","DOI":"10.3390\/cancers12030693"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cam4.2706","article-title":"Driver Genes as Predictive Indicators of Brain Metastasis in Patients with Advanced NSCLC: EGFR, ALK, and RET Gene Mutations","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_20","first-page":"PO.18.00386","article-title":"Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A Transforming KIF5B and RET Gene Fusion in Lung Adenocarcinoma Revealed from Whole-Genome and Transcriptome Sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","article-title":"Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas","volume":"3","author":"Drilon","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1158\/0008-5472.CAN-17-0109","article-title":"EGFR Mediates Responses to Small Molecule Drugs Targeting Oncogenic Fusion Kinases","volume":"77","author":"Vaishnavi","year":"2017","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00280-017-3283-z","article-title":"A Phase Ib\/II Study of Cabozantinib (XL184) with or without Erlotinib in Patients with Non-Small Cell Lung Cancer","volume":"79","author":"Wakelee","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, Cabozantinib, or Erlotinib plus Cabozantinib as Second- or Third-Line Treatment of Patients with EGFR Wild-Type Advanced Non-Small Cell Lung Cancer (ECOG-ACRIN 1512): A Phase 2 Randomised Controlled Trial","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_28","first-page":"7284","article-title":"ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III Trial of Vandetanib Compared with Erlotinib in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib Versus Placebo in Patients with Advanced Non-Small-Cell Lung Cancer after Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus Docetaxel versus Docetaxel as Second-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer (ZODIAC): A Double-Blind, Randomised, Phase 3 Trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial","volume":"29","author":"Arrieta","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","article-title":"Vandetanib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer-Harboring RET Rearrangement: A Phase II Clinical Trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in Patients with Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer (LURET): An Open-Label, Multicentre Phase 2 Trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in Management of Solid Tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8043","DOI":"10.1200\/jco.2014.32.15_suppl.8043","article-title":"E7080 (Lenvatinib) in Addition to Best Supportive Care (BSC) versus BSC Alone in Third-Line or Greater Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)","volume":"32","author":"Havel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A Phase 2 Study of Lenvatinib in Patients with RET Fusion-Positive Lung Adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET Kinase Inhibition for Patients with RET-Altered Cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Drilon, A., Oxnard, G.R., Tan, D.S.W., Loong, H.H.F., Johnson, M., Gainor, J., McCoach, C.E., Gautschi, O., Besse, B., and Cho, B.C. (2020). Efficacy of Selpercatinib in RET Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2005653"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2018.36.15_suppl.102","article-title":"A Phase 1 Study of LOXO-292, a Potent and Highly Selective RET Inhibitor, in Patients with RET-Altered Cancers","volume":"36","author":"Drilon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET-Rearranged Lung Cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision Targeted Therapy with BLU-667 for RET-Driven Cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients (Pts) with Advanced RET-Fusion+ Non-Small Cell Lung Cancer (NSCLC)","volume":"37","author":"Gainor","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"ix122","DOI":"10.1093\/annonc\/mdz431","article-title":"Treatment with Pralsetinib (Formerly BLU-667), a Potent and Selective RET Inhibitor, Provides Rapid Clearance of CtDNA in Patients with RET-Altered Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9515","DOI":"10.1200\/JCO.2020.38.15_suppl.9515","article-title":"Registrational Dataset from the Phase I\/II ARROW Trial of Pralsetinib (BLU-667) in Patients (Pts) with Advanced RET Fusion+ Non-Small Cell Lung Cancer (NSCLC)","volume":"38","author":"Gainor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon-2020-0935","article-title":"Phase III Study of Selpercatinib versus Chemotherapy \u00b1 Pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer","volume":"17","author":"Solomon","year":"2021","journal-title":"Futur. Oncol."},{"key":"ref_50","unstructured":"Hoffmann-La Roche (2021, August 29). A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04222972."},{"key":"ref_51","unstructured":"Hoffmann-La Roche (2021, August 29). A Phase II\/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03178552."},{"key":"ref_52","unstructured":"Fondazione per la Medicina Personalizzata (2021, August 29). The Rome Trial from Histology to Target: The Road to Personalize Target Therapy and Immunotherapy, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04591431."},{"key":"ref_53","unstructured":"Southwest Oncology Group (2021, August 29). A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04268550."},{"key":"ref_54","unstructured":"Ardizzoni, A. (2021, August 29). Phase II Study to Evaluate the Activity and Safety of Cabozantinib in Pretreated, Advanced RET-Rearranged Non-Small Cell Lung Cancer Patients: CRETA Trial, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04131543."},{"key":"ref_55","unstructured":"European Thoracic Oncology Platform (2021, August 29). A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-Rearranged Advanced NSCLC, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03445000."},{"key":"ref_56","unstructured":"National Cancer Institute (NCI) (2021, August 29). A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03468985."},{"key":"ref_57","unstructured":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd (2021, August 31). A Randomized, Double-Blind, Multicenter, Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Subjects With Squamous Non-Small Cell Lung Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04439890."},{"key":"ref_58","unstructured":"Merck Sharp & Dohme Corp (2021, August 29). A Phase 3, Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080\/MK-7902) in Participants With Treatment-Na\u00efve, Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have a Tumor Proportion Score (TPS) Greater Than or Equal to 1% (LEAP-007), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03829332."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/15384047.2020.1806643","article-title":"Enhanced Antitumor Effect of Alectinib in Combination with Cyclin-Dependent Kinase 4\/6 Inhibitor against RET-Fusion\u2013Positive Non\u2013Small Cell Lung Cancer Cells","volume":"21","author":"Fujimura","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1200\/JCO.2018.36.15_suppl.9035","article-title":"Multi-Kinase RET Inhibitor Vandetanib Combined with MTOR Inhibitor Everolimus in Patients with RET Rearranged Non-Small Cell Lung Cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small-Cell Lung Cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion\u2013Positive Lung Cancer by Combining Selpercatinib with Crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2020.38.15_suppl.3616","article-title":"The Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Na\u00efve RET-Driven Cancer Models","volume":"38","author":"Drilon","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.21037\/tlcr-20-346","article-title":"Decade in Review: A New Era for RET-Rearranged Lung Cancers","volume":"9","author":"Choudhury","year":"2020","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:54:13Z","timestamp":1760165653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":65,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174415"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174415","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}